218 results on '"Cohen, A.D."'
Search Results
2. P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
3. B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
4. Chronic urticaria and the metabolic syndrome: a cross‐sectional community‐based study of 11 261 patients
5. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real‐life data from PSONET registries
6. Chronic urticaria and atopic disorders: a cross‐sectional study of 11 271 patients
7. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
8. Expanding the skin and histopathology manifestations of autoinflammatory diseases
9. An integrated safety analysis of treatment‐emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies
10. The underestimated risk for complications in immunocompetent patients with herpes zoster: should we change our clinical practice?
11. 224 Comorbidities and healthcare utilization in 4,197 patients with prurigo nodularis: A cross-sectional population-based analysis
12. Is Bridging Radiation (RT) Safe with B Cell Maturation Antigen–targeting Chimeric Antigenic Receptor T Cells (CART-BCMA) Therapy?
13. Anti‐psoriatic therapies and cardiovascular risk: is there a difference between different systemic agents?
14. Clinical criteria and sensitivity – what should be preferred when we tackle highly conflicting issues Response to ‘Metabolic syndrome and atopic dermatitis: reconsidering the definition criteria’
15. Drug survival in patients with psoriasis is associated with the availability of biologic medications
16. Hidradenitis suppurativa and infections
17. Treatment and clinical outcomes in anti‐p200 pemphigoid: a systematic review
18. Hidradenitis suppurativa and schizophrenia: a nationwide cohort study
19. IL-15: targeting CD8+ T cells for immunotherapy
20. Measuring surface properties and oxidation of coal macerals using the atomic force microscope
21. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need
22. Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia
23. The association between the socioeconomic status and anxiety–depression comorbidity in patients with psoriasis: a nationwide population‐based study
24. Incidence and prevalence of psoriasis in Israel between 2011 and 2017
25. PS1372 B-CELL MATURATION ANTIGEN ANTIBODY-DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I STUDY
26. Atopic dermatitis and the metabolic syndrome: a cross‐sectional study of 116 816 patients
27. 慢性荨麻疹和骨质疏松
28. Chronic urticaria and osteoporosis
29. The epidemiology of hidradenitis suppurativa: what do we know?
30. Mobilization of major inorganic ions during experimental diagenesis of characterized peats
31. Hidradenitis suppurativa and schizophrenia: a nationwide cohort study.
32. Treatment and clinical outcomes in anti‐p200 pemphigoid: a systematic review.
33. Pemphigus and smoking - insights from a big data analysis
34. THU0506 Cross-sectional analysis of the associations between fibromyalgia and cancer
35. FRI0481 Giant cell arteritis and inflammatory bowel disease – is there a connexion? results from a population-based study
36. SAT0545 Giant cell arteritis and hematologic malignancies: a real-life experience
37. SAT0690 The association between sarcoidosis and ischaemic heart disease – a big data analysis
38. OP0087 Increased risk of ischaemic heart disease and mortality among fmf patients – perspective from a big database
39. 化脓性汗腺炎研究的核心结果的全球共识:历史性共识会议I和II的更新
40. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II
41. Chronic urticaria and irritable bowel syndrome: a cross-sectional study of 11 271 patients
42. The Investigated Question and Study Design in Cross-sectional Studies Response to ‘Chronic Urticaria and the Metabolic Syndrome: a Cross-sectional Community-based Study of 11,261 Patients’: Authors' Reply
43. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice
44. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries
45. Combining organic petrography and palynology to assess anthropogenic impacts on peatlands: Part 2. An example from a Carolina Bay wetland at the Savannah River Site in South Carolina
46. Combining organic petrography and palynology to assess anthropogenic impacts on peatlands: Part 1. An example from the northern Everglades of Florida
47. Hidradenitis suppurativa and sleep disorders: a population‐based study.
48. Chronic urticaria and the metabolic syndrome: a cross-sectional community-based study of 11 261 patients
49. Introducing global peat-specific temperature and pH calibrations based on brGDGT bacterial lipids
50. The association between systemic lupus erythematosus and bipolar disorder – a big data analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.